Technical data sheet · API offerings

PRL-8-53 API — Technical Data Sheet

CAS Registry Number: 51352-87-5 · Therapeutic Category: Nootropics

Memory-enhancement research compound PRL-8-53 — high-purity analytical reference standard. Purity 98% min. Molecular formula C18H21NO2. Physical form: White or off-white powder. CAS Registry Number: 51352-87-5. Supplied in 100g, 500g, 1kg+ quantities from $2.0…

Contents

  1. Substance identity
  2. Longshine Boi-Tech offerings
  3. Pharmacopoeial specifications
  4. Impurity profile & stability
  5. Regulatory filings & documentation
  6. Packaging, storage & shipping
  7. Commercial supply terms

1. Substance identity

API namePRL-8-53
CAS Registry Number51352-87-5
Therapeutic CategoryNootropics
API TechnologySynthetic / semi-synthetic (molecule-specific route)
Pharmacopoeial referenceUSP · Ph. Eur. · IP · JP — per-buyer specification
ManufacturerLongshine Boi-Tech Pvt. Ltd., Pune, India
Quality systemWHO-GMP · ISO 9001:2015 · ICH Q7 · ICH Q11

2. Longshine Boi-Tech offerings for PRL-8-53

Memory-enhancement research compound PRL-8-53 — high-purity analytical reference standard. Purity 98% min. Molecular formula C18H21NO2. Physical form: White or off-white powder. CAS Registry Number: 51352-87-5. Supplied in 100g, 500g, 1kg+ quantities from $2.00/g entry for laboratory research, analytical method development, and reference-standard applications. Research use only — not for human or animal consumption.

We supply PRL-8-53 to nootropics buyers across 50+ countries — generic drug manufacturers, CDMOs, hospital pharmacies, research institutions, and contract formulators. Letter of Authorization referencing our active DMF / CEP is issued at no charge to qualified buyers for ANDA, IND, NDA, EU Marketing Authorisation, MHRA UKMA, ANVISA, PMDA, and other regulatory pathways.

3. Pharmacopoeial specifications

PRL-8-53 is released against the buyer's chosen pharmacopoeia — USP, Ph. Eur., IP, or JP — with the destination market determining the default. The same lot can carry multiple pharmacopoeial certifications where the monographs align. Specification highlights routinely reported on each Certificate of Analysis (CoA) include:

4. Impurity profile & stability

Each PRL-8-53 batch ships with a full impurity profile — identified, qualified, and reported per ICH Q3A and Q3B guidelines. Process-related impurities are characterised in the DMF Restricted Part; degradation products are characterised through forced-degradation studies (acid, base, oxidation, thermal, photolysis) and reported in the stability dossier. ICH-compliant stability data is available on accelerated (40°C / 75% RH) and long-term (25°C / 60% RH or 30°C / 65% RH per ICH zone) conditions — typically 6 months accelerated and 24 to 36 months long-term depending on the molecule. Photostability per ICH Q1B option 2 is included.

5. Regulatory filings & documentation

Active regulatory dossiers maintained for PRL-8-53 (or compatible LoA support):

JurisdictionFiling typeDocumentation
United StatesFDA Type II DMFLetter of Authorization within 24 business hours; DMF number disclosed under MNDA
European UnionEDQM CEP or ASMFCEP certificate or ASMF Restricted/Applicant's Part dossier
United KingdomMHRA UKMA / Windsor FrameworkCEP-based recognition; UK-specific reference letter
BrazilANVISA RDC 359/2020Portuguese-language CMC package + reference letter
CanadaHealth Canada DMFCross-reference of US FDA DMF
JapanPMDA J-DMFJP-grade release with Japanese-language label data
KoreaMFDS DMFKP-grade release
GCC regionSFDA dossier supportReference letters and CMC packages

Each CoA carries the manufacturing date, batch number, retest date, and a QR-style traceability identifier linked to the batch manufacturing record. Per ICH Q7 requirements, retain samples are held for two years past the API expiry.

6. Packaging, storage & shipping

7. Commercial supply terms

WHO-GMP & ISO 9001:2015 certified. Active US FDA DMF and EDQM CEP filings. Pharmacopoeial release against USP, Ph. Eur., IP, JP. CoA on every batch. First-shipment lead time 7-10 business days. Letter of Authorization within 24 business hours of supply agreement.
Request commercial quote Product page Interactive catalogue Order a sample